Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.4K
Diabetes Mellitus: Introduction01:26

Diabetes Mellitus: Introduction

18
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and...
18
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

57
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
57
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

3.9K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.9K
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

19
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
19
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

40
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1...
40

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study.

Endocrine journal·2025
Same author

Genetic and Clinical Characteristics of Monogenic Diabetes in Japan: A Nationwide Study by the Japan Diabetes Society.

The Journal of clinical endocrinology and metabolism·2025
Same author

PIK3R1 mutations in individuals with insulin resistance or growth retardation: Case series and in silico functional analysis.

Journal of diabetes investigation·2025
Same author

Cutoff value of serum 25-hydroxyvitamin D leading to vitamin D deficiency for children in Japan.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology·2025
Same author

<i>ABCC8</i> haploinsufficiency in a mother-daughter pair with young-onset diabetes with and without neonatal hypoglycemia.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology·2025
Same author

A case of diffuse congenital hyperinsulinism in which continuous glucose monitoring contributed to the choice of a treatment strategy following a subtotal pancreatectomy.

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology·2024

Related Experiment Video

Updated: Apr 26, 2026

Isolation, Culture, and Imaging of Human Fetal Pancreatic Cell Clusters
08:09

Isolation, Culture, and Imaging of Human Fetal Pancreatic Cell Clusters

Published on: May 18, 2014

14.7K

Congenital hyperinsulinism: current status and future perspectives.

Tohru Yorifuji1

  • 1Department of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka, Japan.

Annals of Pediatric Endocrinology & Metabolism
|August 1, 2014
PubMed
Summary

Recent advances in understanding congenital hyperinsulinism (CHI) have improved patient outcomes. New diagnostic tools and treatments, like (18)F-fluoro-L-DOPA PET scans, offer better management and cure rates for CHI.

Keywords:
CongenitalHyperinsulinismHypoglycemia

More Related Videos

Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat
11:12

Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat

Published on: February 7, 2011

54.0K
An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.5K

Related Experiment Videos

Last Updated: Apr 26, 2026

Isolation, Culture, and Imaging of Human Fetal Pancreatic Cell Clusters
08:09

Isolation, Culture, and Imaging of Human Fetal Pancreatic Cell Clusters

Published on: May 18, 2014

14.7K
Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat
11:12

Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat

Published on: February 7, 2011

54.0K
An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.5K

Area of Science:

  • Endocrinology
  • Genetics
  • Pediatric Medicine

Background:

  • Congenital hyperinsulinism (CHI) management has significantly improved.
  • Understanding the molecular and pathological basis of CHI is key to progress.
  • Severe psychomotor delay is now rare in CHI patients.

Purpose of the Study:

  • To review recent developments in the diagnosis and treatment of CHI.
  • To discuss the molecular basis and genetic etiologies of CHI.
  • To highlight unsolved questions in CHI research.

Main Methods:

  • Review of molecular and pathological findings in CHI.
  • Discussion of diagnostic advancements, including (18)F-fluoro-L-DOPA PET.
  • Analysis of current and emerging therapeutic strategies for CHI.

Main Results:

  • Inactivating mutations in KATP channel genes (ABCC8, KCNJ11) and others are known etiologies.
  • (18)F-fluoro-L-DOPA PET has revolutionized focal CHI detection and management.
  • Pharmacological treatments (diazoxide, octreotide, lanreotide) reduce the need for pancreatectomy.

Conclusions:

  • Improved understanding of CHI genetics and diagnostics has led to better patient outcomes.
  • Novel therapeutic agents show promise for managing CHI.
  • Further research is needed to identify all CHI genes and understand transient CHI and spontaneous remission mechanisms.